Format

Send to

Choose Destination
Pharmacotherapy. 2017 Apr;37(4):412-419. doi: 10.1002/phar.1905. Epub 2017 Mar 10.

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment.

Author information

1
Missouri Baptist Medical Center, St. Louis, Missouri.
2
Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri.

Abstract

STUDY OBJECTIVE:

The U.S. Food and Drug Administration approval of the use of apixaban in patients with a creatinine clearance (CrCl) of < 15 ml/minute or in those receiving dialysis is based only on pharmacokinetic data as clinical trials of apixaban excluded patients with a CrCl of < 25 ml/minute or a serum creatinine concentration (SCr) of > 2.5 mg/dl. Thus, the objective of this study was to evaluate the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment.

DESIGN:

Retrospective, matched-cohort study.

SETTING:

Community hospital.

PATIENTS:

A total of 146 adults who received at least one dose of apixaban (73 patients) or warfarin (73 patients) while hospitalized between January 30, 2014, and December 31, 2015, and had a CrCl of < 25 ml/minute or SCr of > 2.5 mg/dl, or who received peritoneal dialysis or hemodialysis, were included. Patients who were taking warfarin and had a therapeutic international normalized ratio on admission were matched consecutively in a 1:1 fashion in chronologic order to patients taking apixaban based on renal function and indication for anticoagulation.

MEASUREMENTS AND MAIN RESULTS:

The primary outcome was major bleeding. Secondary outcomes included the composite of bleeding (major bleeding, clinically relevant nonmajor bleeding, and minor bleeding) in addition to documented ischemic stroke or recurrent venous thromboembolism. A nonsignificant difference in the occurrence of major bleeding and composite bleeding was observed between patients who received apixaban compared with those who received warfarin (9.6% vs 17.8%, p=0.149, and 21.9% vs 27.4%, p=0.442, respectively). The occurrence of stroke was similar between the groups (7.5% in each group), and no recurrent venous thromboembolism events were noted in either group during the study period.

CONCLUSION:

Apixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.

KEYWORDS:

anticoagulation; cardiology; dialysis; end-stage renal disease; renal failure

PMID:
28117916
DOI:
10.1002/phar.1905
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center